Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

short term income and recurring revenue streams from a successful product launch in the future.

Regulatory strategy

CeNeS preferred strategy is for a partner to be involved in the key decisions regarding regulatory filing strategies both in Europe and in United States. The strategy in the USA is clear. The strong data obtained from the most recent Phase III study validates the proposed product profile of M6G and strengthens CeNeS position with potential North American partners. Registration could be achieved in the USA in 2009 after conducting two Phase III studies to the requirements of the FDA. It is important to note that the quality and robustness of the clinical data produced by the current study significantly reduces the risk for the development of M6G by enabling optimal trial design and the selection of endpoints in the remaining Phase III studies.

In Europe the narrow failure to achieve statistical significance with the second chosen primary endpoint of incidence and severity of nausea (p=0.052 not p<0.050) offers three options:

1) Pursue a filing application in certain European countries with the comprehensive clinical data package that CeNeS has assembled. 2) Further strengthen the European package by conducting an additional European Phase III study which would complete in 2008 with product filing in 2009. 3) Use the USA Phase III trials to support the European application, potentially with a global partner.

CeNeS will continue to discuss the above strategies with regulatory consultants and potential partners.

Neil Clark, Chief Executive of CeNeS commented "The ongoing analysis of the Phase III results further confirms our belief in the excellent potential of M6G as a novel product for post- operative pain. The quality and breadth of the data contained in this large study supports M6G's anticipated product profile.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... Calif. , July 30, 2015  Amgen (NASDAQ: ... , partner and managing director of Warburg Pincus LLC, to ... pleased to welcome Fred Hassan and the deep, ... Amgen Board," said Robert A. Bradway , chairman and ... commitment to innovation will serve Amgen well." Mr. ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 2011  SRI International has been awarded a contract worth ... National Institute of Allergy and Infectious Diseases (NIAID), part ... award will allow SRI to continue a program that ... in the translation of basic research into clinical applications. ...
... CENTER VALLEY, Pa., Dec. 14, 2011 /PRNewswire-iReach/ ... portfolio by introducing a collection of EZ Shot 2 ... unique needles offer excellent puncture capability along with an ... the targeted site. Available in a complete selection of ...
Cached Medicine Technology:SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 2SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 3Olympus Broadens Portfolio With a Suite of New Single-Use Aspiration Needles 2
(Date:7/31/2015)... Vegas, NV (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... Vegas at the MGM Grand Garden Arena. Fans of every genre of music will ... Friday, September 18th, the first day of the festival, the following artists will perform: ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of ... Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto ... in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, ...
(Date:7/31/2015)... ... 2015 , ... Ticket Down is a reliable source for authentic tickets for ... Park. The festival will end on Sunday, August 2nd. , Music ... Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment from ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... odor to get the job done, study shows , FRIDAY, Oct. ... scent to manipulate pollinating insects, a new study reveals. , Cycads, ... million to 290 million years, look similar to ferns or palms ... that also includes modern coniferous tress such as pines and firs. ...
... Relationships between, Hospitals, Coding and Patient Financial Services Departments to ... ... PHILADELPHIA, Oct. 5 CareTech Solutions, an information,technology (IT) and ... announced today that Charlie Robinson,RHIT, CCS-P, iDoc(TM) Implementation Manager, will ...
... displacement, forced labor, attacks by soldiers on civilians, injury ... have been widespread in eastern Burma (also known as ... reporting incidents in the 12 months prior to a ... Johns Hopkins Bloomberg School of Public Health, Back Pack ...
... put in their,current Medicare prescription drug plans, the ... monthly premiums for 2008, says new analysis,released by ... and its proprietary DataFrame(R),database, Avalere experts computed an ... marketplace. Under this method, the premiums of,plans with ...
... Dystonia-Affected Man Files Lawsuit Against U.S. Airways for Denying Right, to Fly; ... ... Disabilities, JACKSONVILLE, Fla., Oct. 5 A ... June, has sued the major,airline for discrimination. Andy Gates is affected ...
... Results from two,studies comparing colorectal cancer screening ... called virtual colonoscopy),have sparked interest in colorectal cancer ... consumers. The studies, one a large multi-center,trial sponsored ... other from the,University of Wisconsin published in the ...
Cached Medicine News:Health News:CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit 2Health News:Human rights violations widespread in eastern Burma 2Health News:Human rights violations widespread in eastern Burma 3Health News:Average Medicare Prescription Drug Premiums to Rise 21% 2Health News:Major US Airline Discriminates Against Disabled Passenger, Lawsuit Charges 2Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 2Health News:Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: